Floatz logo

cp-383

Solid Tumor Malignancies

Tasca TherapeuticsPhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

27 Active assets in the Solid Tumor Malignancies cohort.

Asset / SponsorPhaseRating
Olutasidenib
Rigel Pharmaceuticals
Phase 4B
Cyclophosphamide
University of Kansas Medical Center
Phase 3B
Pembrolizumab
University of Kansas Medical Center
Phase 3B
Epirubicin
University of Kansas Medical Center
Phase 3B
Nivolumab
University of Kansas Medical Center
Phase 3CCC

View all 35 →

Same molecule, other indications

cp-383 is also rated in:

head and neck squamous cell carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
small cell lung carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
colorectal carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →